Research Article

Association between XPD Lys751Gln polymorphism and risk of head and neck cancer: a meta-analysis

Published: December 08, 2011
Genet. Mol. Res. 10 (4) : 3356-3364 DOI: https://doi.org/10.4238/2011.November.22.6
Cite this Article:
H. Yuan, Y.M. Niu, R.X. Wang, H.Z. Li, N. Chen (2011). Association between XPD Lys751Gln polymorphism and risk of head and neck cancer: a meta-analysis. Genet. Mol. Res. 10(4): 3356-3364. https://doi.org/10.4238/2011.November.22.6
3,165 views

Abstract

Several studies have investigated the association between Lys751Gln polymorphism in the xeroderma pigmentosum group D (XPD) gene and risk of head and neck cancer; however, the published results are conflicting. We conducted a meta-analysis that comprised 15 published case-control studies examining the association of head and neck cancer risk with XPD Lys751Gln polymorphism in different populations, based on the data identified in Medline up to November 2010. Odds ratios (ORs) with 95% confidence intervals (CI) were used to assess the strength of the association. Overall, significantly elevated head and neck cancer risk was associated with XPD Lys751Gln polymorphism when all studies were pooled into the meta-analysis [(Gln/Gln + Lys/Gln) vs Lys/Lys: OR = 1.12, 95%CI = 1.03-1.22, P < 0.01, heterogeneity P = 0.11]. In the subgroup analysis by ethnicity, borderline significantly increased risk was found for Europeans [(Gln/Gln + Lys/Gln) vs Lys/Lys: OR = 1.11, 95%CI = 1.00-1.23, P < 0.05]. In conclusion, our meta-analysis demonstrated that XPD Lys751Gln polymorphism could be a prediction marker for risk of head and neck cancer.

Several studies have investigated the association between Lys751Gln polymorphism in the xeroderma pigmentosum group D (XPD) gene and risk of head and neck cancer; however, the published results are conflicting. We conducted a meta-analysis that comprised 15 published case-control studies examining the association of head and neck cancer risk with XPD Lys751Gln polymorphism in different populations, based on the data identified in Medline up to November 2010. Odds ratios (ORs) with 95% confidence intervals (CI) were used to assess the strength of the association. Overall, significantly elevated head and neck cancer risk was associated with XPD Lys751Gln polymorphism when all studies were pooled into the meta-analysis [(Gln/Gln + Lys/Gln) vs Lys/Lys: OR = 1.12, 95%CI = 1.03-1.22, P + Lys/Gln) vs Lys/Lys: OR = 1.11, 95%CI = 1.00-1.23, P XPD Lys751Gln polymorphism could be a prediction marker for risk of head and neck cancer.